This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Abbott signs pact with Novo Nordisk to offer semaglutide

Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SUgAmZw
via IFTTT

Lupin receives USFDA EIR for Goa facility with VAI status

Drug maker Lupin said it has received an Establishment Inspection Report from the US Food and Drug Administration for its Goa-based manufacturing facility, with a Voluntary Action Indicated classification following a November 2025 inspection.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rp3wNg6
via IFTTT

India moves closer to dengue vaccine as final trials underway

An Indian vaccine candidate, DengiAll, is in its final testing phase. This single-dose shot offers hope against the deadly dengue disease. Over 10,000 volunteers are participating in the trials. If successful, DengiAll could be available next year. This development is crucial for India and other lower-middle-income countries facing rising dengue cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4RBklXJ
via IFTTT

Dräger India collaborates with Breach Candy Hospital to advance clinical education

Dräger India and Breach Candy Hospital have partnered to enhance clinical education and skill development for healthcare professionals. This collaboration brings the Dräger Medical Academy to Mumbai, offering digital learning modules and VR-based simulation training to bridge skill gaps and improve patient safety. The initiative aims to foster continuous learning and readiness in India's evolving healthcare landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n4tzOLc
via IFTTT

Navigating environmental shifts: How proactive hygiene shapes a child's future

In today's unpredictable climate, raising children requires a proactive approach to health beyond traditional methods. Savlon Swasth India Mission's podcast, The Doc's Pod, emphasizes science-backed hygiene practices as a strategic tool for physical empowerment. By integrating habits like regular handwashing and surface sanitization, families can build a robust foundation for enduring health and cognitive development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nha8Qw1
via IFTTT

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has secured approval from the US health regulator for a generic seizure medication. The company received final clearance from the USFDA for Lamotrigine orally disintegrating tablets. This drug is therapeutically equivalent to GlaxoSmithKline's Lamictal. It is used for various seizure types in patients aged two and older. The market for this medication is estimated at USD 27 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1U7YSVz
via IFTTT

Zydus plans launch of semaglutide generic in reusable pen form

Zydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under brand names Semaglyn, Mashema, and Altreme. Zydus will offer a unique reusable pen for easier dosage adjustment. This move aims to simplify treatment for patients managing Type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fEWJ2gU
via IFTTT